These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20418034)

  • 1. The HER3/ErbB3 receptor: a promising target in cancer drug therapy.
    Desbois-Mouthon C
    Gastroenterol Clin Biol; 2010; 34(4-5):255-9. PubMed ID: 20418034
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-epidermal growth factor receptor strategies for advanced breast cancer.
    Campos SM
    Cancer Invest; 2008 Oct; 26(8):757-68. PubMed ID: 18853311
    [No Abstract]   [Full Text] [Related]  

  • 3. Foreword.
    Chen HX; Cleck JN; Coelho R; Dancey JE
    Curr Probl Cancer; 2009; 33(4):244. PubMed ID: 20082841
    [No Abstract]   [Full Text] [Related]  

  • 4. Epidermal growth factor receptor inhibitors: current status and future directions.
    Chen HX; Cleck JN; Coelho R; Dancey JE
    Curr Probl Cancer; 2009; 33(4):245-94. PubMed ID: 20082842
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting ADAMS and ERBBs in lung cancer.
    Hynes NE; Schlange T
    Cancer Cell; 2006 Jul; 10(1):7-11. PubMed ID: 16843261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of HER-2 inhibitors.
    Rabindran SK
    Cancer Lett; 2005 Sep; 227(1):9-23. PubMed ID: 16051028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
    Chen X; Yeung TK; Wang Z
    Biochem Biophys Res Commun; 2000 Nov; 277(3):757-63. PubMed ID: 11062025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-1, 2, and 3.
    Gettinger S
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1793-6. PubMed ID: 22005533
    [No Abstract]   [Full Text] [Related]  

  • 9. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
    Zhou CC; Deng XF
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):138-40. PubMed ID: 17445479
    [No Abstract]   [Full Text] [Related]  

  • 12. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A; Vidal L; Shaw H; de Bono J
    Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
    Normanno N; Maiello MR; De Luca A
    J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The HER3/ERBB3 receptor: the dark side of the ERBB planet].
    Larbouret C; Gaborit N; Poul MA; Pèlegrin A; Chardès T
    Med Sci (Paris); 2015 May; 31(5):465-8. PubMed ID: 26059291
    [No Abstract]   [Full Text] [Related]  

  • 15. Array-based pharmacogenomics of molecular-targeted therapies in oncology.
    Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D
    Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
    Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
    Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
    Verlingue L; Hollebecque A; Lacroix L; Postel-Vinay S; Varga A; El Dakdouki Y; Baldini C; Balheda R; Gazzah A; Michot JM; Marabelle A; Mir O; Arnedos M; Rouleau E; Solary E; De Baere T; Angevin E; Armand JP; Michiels S; André F; Deutsch E; Scoazec JY; Soria JC; Massard C
    Eur J Cancer; 2018 Mar; 92():1-10. PubMed ID: 29413684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population differences in the use of EGFR-targeted agents.
    Saijo N
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):730-2. PubMed ID: 18997662
    [No Abstract]   [Full Text] [Related]  

  • 19. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.
    Kiavue N; Cabel L; Melaabi S; Bataillon G; Callens C; Lerebours F; Pierga JY; Bidard FC
    Oncogene; 2020 Jan; 39(3):487-502. PubMed ID: 31519989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of HKI-272 and related compounds for the treatment of cancer.
    Wissner A; Mansour TS
    Arch Pharm (Weinheim); 2008 Aug; 341(8):465-77. PubMed ID: 18493974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.